Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2504 | Nasal Swab Wiki | 0.71 |
| drug1051 | Convalescent Plasma 2 Units Wiki | 0.71 |
| drug1745 | Home Sleep Apnea Testing or In-hospital Polysomnography Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001049 | Apnea NIH | 0.50 |
| D020181 | Sleep Apnea, Obstructive NIH | 0.32 |
| D012891 | Sleep Apnea, NIH | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002104 | Apnea HPO | 0.50 |
| HP:0002870 | Obstructive sleep apnea HPO | 0.32 |
| HP:0010535 | Sleep apnea HPO | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002090 | Pneumonia HPO | 0.04 |
Navigate: Correlations HPO
There are 2 clinical trials
This is a prospective, epidemiological, cohort study to assess the feasibility of screening healthy asymptomatic workers for the presence of severe acute respiratory syndrome SARS-CoV-2 by pharyngeal swaps and serology at baseline, day 21 and day 40.
Description: Evaluation of immune responses to components of SARS-CoV-2 as well as evaluation of Swab for the presence of SARS-CoV-2 by PCR. Determination of the difference between the study groups in anti-SARS-CoV 2 seropositivity status. Analysis of trends in CD4/CD8 concentrations over time and correlation with immunoglobulin G (IgG) Levels and new assay evaluation.
Measure: Immune responses to components of SARS-Cov-2 Time: up to visit 3 (day 40)Description: Evaluation of Swab for the presence of SARS-CoV-2 by PCR and determination of the difference between the study groups in anti-SARS-CoV 2 seropositivity status.
Measure: Swabs for the presence of SARSCoV-2 Time: up to visit 3 (day 40)Description: Evaluation of immune responses to components of SARS-CoV-2 as well as evaluation of Swab for the presence of SARS-CoV-2 by PCR. Determination of the difference between the study groups in anti-SARS-CoV 2 seropositivity status and analysis of trends in CD4/CD8 concentrations over time and correlation with IgG Levels as well as new assay evaluation.
Measure: Difference between the study groups in anti-SARS-CoV 2 seropositivity status Time: up to visit 3 (day 40)Performance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference method.
Description: Evaluation of performance of the device versus a reference method using standard qualitative comparison techniques (Percent Agreement)
Measure: Performance Evaluation Time: 4 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports